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The current role of chemotherapy in pancreatic carcinoma is limited, and progress in the treatment of this disease represents
a signiﬁcant challenge to medical oncology. The most promising drug under study is gemcitabine, a relatively new
antimetabolite that represents an attractive candidate for combination chemotherapy because of its excellent side-effect
proﬁle and the absence of overlapping toxicities with other chemotherapeutic agents. Combined administration of gemcitabine
and anthracyclines could result in the induction of DNA breaks that are not easily repaired by the cell’s machinery, thus
enhancing the apoptotic signals triggered by these lesions. Forty-four patients with locally advanced and/or metastatic
pancreatic adenocarcinoma were enrolled in this multicenter study. Patients received Epirubicin 20 mg m
72 for 3 weeks
followed by 1 week of rest (1 cycle) and gemcitabine 1000 mg m
72 after Epirubicin on the same day. All were assessable for
toxicity and response, 11 patients responded to treatment with one complete response and 10 partial responses, for an
overall response rate of 25%. Median survival was 10.9 months (range, 2–26 months). Therapy was well tolerated, with a low
incidence of haematologic grade 42 toxicity. A total of 12 of 27 (44.4%) eligible patients attained a clinical beneﬁt response.
Our ﬁndings suggest that the gemcitabine-epirubicin schedule is active and well tolerated in patients with advanced pancreatic
cancer.
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Locally advanced and/or metastatic pancreatic cancer is an aggres-
sive and rapidly fatal disease that represents the ﬁfth most common
cause of cancer-related mortality in the United States and Europe
(Jensen et al, 1990; Parker et al, 1997). Although advances have
been made in the diagnosis and treatment of many gastrointestinal
malignancies, no such progress has been made in pancreatic cancer.
Consequently, median survival from the time of diagnosis ranges
from 3 to 6 months for patients with unresectable disease (Brennan
et al, 1993).
Treatment with single-agent 5-ﬂuorouracil (5-FU) produces
tumour response rates in the range of 0–20%, with little addi-
tional response when used in combination therapy, and no
impact on survival (Brennan et al, 1993). In locally advanced
pancreatic cancer, the combination of chemotherapy with radio-
therapy has not gained much support (Klaassen et al, 1985).
These disappointing results underline the need for new active
agents in pancreatic cancer. Among these, paclitaxel, docetaxel,
topotecan, and temozolomide have shown only limited activity,
with response rates of 5–17% in phase II studies (van Riel et al,
1999). In contrast, gemcitabine (GEM), a relatively new nucleoside
antimetabolite that inhibits DNA synthesis through a number of
mechanisms (Heinemann et al, 1990; Heinemann et al, 1998),
appears to have different properties and activity across a broad
range of solid tumours. In particular, GEM has been more effective
than 5-FU in the alleviation of some disease-related symptoms and
prolongation of survival in patients with advanced pancreatic
cancer (Burris et al, 1997).
On the basis of preclinical studies, GEM represents an attractive
candidate for combination chemotherapy because of its excellent
side-effect proﬁle and the absence of overlapping toxicities with other
chemotherapeutic agents. Moreover, due to its chain termination
masking activity, GEM directly inhibits DNA repair (van Moorsel
et al, 1997), which could represent a molecular basis for synergistic
activity with other DNA-damaging chemotherapeutic agents.
Two of the most potent and widely used DNA-damaging anti-
cancer drugs are doxorubicin and its derivative epirubicin (EPI),
whose primary mechanism of action, as with other anthracycline
derivatives, is the inhibition of topoisomerase II-mediated DNA
resealing and the production of stable DNA breakage. In vitro
studies in solid tumor cell lines have demonstrated that pretreat-
ment of cancer cells with doxorubicin, followed by
administration of GEM, inhibits proliferation and increases the rate
of DNA fragmentation. Thus, the combined administration of
GEM and anthracyclines could result in the induction of DNA
breaks, which are not easily repaired by the cell’s machinery, there-
by enhancing the apoptotic signals triggered by these lesions
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www.bjcancer.com(Angelucci et al, 1997). These data suggest that a treatment sche-
dule of an anthracycline derivative (EPI) in combination with
GEM treatment may be of great therapeutic value in pancreatic
cancer. Moreover, because advanced-stage pancreatic cancer is
frequently accompanied by debilitating symptoms (Schnall and
Macdonald, 1996), we designed a phase II trial to quantify the
effect of GEM-EPI administration on clinical beneﬁt response as
well as objective responses and median survival in patients with
advanced pancreatic cancer.
PATIENTS AND METHODS
Patient eligibility
Patients eligible for the trial had a histologic or cytologic diagnosis
of pancreatic carcinoma with locally advanced unresectable or
metastatic bidimensionally measurable disease. Other eligibility
criteria included age 475 years; Karnofsky’s performance status
440; no prior chemotherapy, hormone therapy or radiation ther-
apy was allowed.
Baseline haematologic requirements included a leukocyte count
53500 ml, hemoglobin 59.5 g dl
71, and platelet count
5100000 ml. Patients were required to have a total bilirubin
42.0 mg dl
71, aspartate aminotransferase (AST) and alanine
aminotransferase (ALT) 436the respective upper limit of normal
(ULN), and prothrombin and activated partial thromboplastin
times 41.56ULN. A serum creatinine 41.5 mg dl
71 and a
measured serum calcium 411.0 mg dl
71 were also required. A
history of myocardial infarction, heart failure, angina, arrhythmia,
or severe hypertension excluded patients from the study.
The study was performed in compliance with the clinical stan-
dards set forth in the Declaration of Helsinki of 1975. Signed
and witnessed informed consent was obtained from each patient
prior to entering the study.
Patient characteristics
Between January 1998 and December 1999, a total of 44 patients,
with a median age of 59 years, from six different institutions were
enrolled in this trial. All patients had a histologic or cytologic diag-
nosis of pancreatic adenocarcinoma. At study entry, most patients
(86%) had a Karnofsky performance score 560, locally advanced
disease (55%), and stage IV disease (77%). Patient characteristics
are detailed in Table 1.
Forty-four patients were assessed for toxicity and response. Two
patients elected to discontinue treatment during the ﬁrst and
second cycles of chemotherapy. Out of the 42 evaluable patients,
27 (64%) with tumour-related symptoms, such as pain, weight loss,
and impaired performance status, were also assessable for clinical
beneﬁt response.
Treatment
EPI 20 mg
2 was administered as an intravenous bolus injection on
day 1, 8, 15 for 3 weeks followed by a week of rest (1 cycle); GEM
diluted in normal saline solution at the dose of 1000 mg m
72 was
administered intraveously over 30 min after EPI on the same day.
Concomitant medications routinely administered before cytotoxic
drugs included ondansetron 8 mg and methyl-prednisolone
40 mg intravenously. Treatment courses continued in patients
who achieved objective response, stable disease, or positive clinical
beneﬁt response until a total of seven courses or until there was
signiﬁcant clinical deterioration because of tumour-related symp-
toms. Patients were not allowed to receive concomitant radiation
therapy or hormonal therapy during the trial.
The toxicities of each course were recorded before the next
course was started and were graded according to World Health
Organization (Miller et al, 1981) criteria. Chemotherapeutic drug
doses were reduced by 25% in the subsequent cycle if the lowest
WBC (absolute granulocyte) count was less than 1000 ml
(500 ml), the lowest platelet count was less than 50000 ml, or if
any severe (WHO grade 53), nonhematologic toxicity was
observed in the previous cycle. Treatment could be delayed for
up to 2 weeks if the WBC count was lower than 3000 ml and/or
a platelet count less than 75000 ml. Granulocyte colony-stimulating
factor (G-CSF) using a 5-day administration schedule was allowed
and if haematological recovery was complete the dose of the
following cycle was re-escalated to 100%-dose.
Baseline and treatment assessments
Before entering the study, all patients underwent a full history and
physical evaluation, complete blood count with differential routine
blood chemistries and ECG and echocardiography to evaluate cardiac
function. Chest X-ray, abdominal ultrasound or computerized tomo-
graphy (CT) scan were performed to deﬁne the measurable lesions
before the start of treatment, every two cycles to evaluate response
and after the seven cycle. Baseline performance status, analgesic
consumption, and pain intensity data were also collected.
Objective tumour assessments and evaluation of clinical beneﬁt
response, a composite measure of pain (analgesic consumption
and pain intensity), performance status, and body weight (Burris
et al, 1997), were determined at the end of every 2 cycles during
chemotherapy and every 3 months after discontinuation of treat-
ment. Tumour measurements were based on the sum of the
products of the bidimensional diameter of the lesions. To be clas-
siﬁed as a complete responder (CR), a patient had to have
complete regression of the disease and be free of symptoms related
to the carcinoma for a minimum of 4 weeks. Patients with greater
than a 50% reduction in lesion size and no new lesions were clas-
siﬁed as partial responders (PR) and minor response for reduction
in lesion size 550%. Patients were rated as having progressive
disease (PD) if any new lesion appeared, if tumour size increased
by 25% over pretreatment measurements, or for deterioration in
clinical status consistent with disease progression. Patients who
failed to meet the criteria of CR, PR, or PD, and who remained
on-study for at least 2 months, were classiﬁed as having stable
disease (SD). Two objective measurements that showed a response
at least 4-week intervals were required to conﬁrm a patients’
response and were assessed by CT and/or abdominal ultrasound
examination: all tumour measurements in patients who responded
were reviewed and conﬁrmed by an independent radiologist
blinded to the sequencing of the scans.
Clinical beneﬁt response criteria
Clinical beneﬁt assessments included evaluations of pain intensity,
analgesic consumption, performance status, and weight (Rothen-
berg et al, 1996; Burris et al, 1997). Analgesic consumption was
computed on a weekly basis as the mean of the daily analgesic
consumption, expressed in terms of morphine equivalent mg
day
71. To be considered clinical beneﬁt responders, patients had
to have more than 1 of the following: a 50% decrease in pain
intensity; a 50% decrease in analgesic consumption; or a 420-
point increase in performance status that was sustained for more
than 4 weeks, without deterioration in any of the other parameters.
For patients who were stable in pain intensity, analgesic consump-
tion, and performance status, a 7% increase in dry body weight was
required for patients to be classiﬁed responders. During the study,
pain intensity was measured daily by the patients using a 10-cm
linear analog scale, and analgesic consumption was based on a
daily diary kept by patients. Performance status and weight were
measured weekly by a nurse. Each patient was classiﬁed as positive,
stable, or negative for each of the primary clinical beneﬁt measures.
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ment over baseline in at least one variable, without a negative
result in any other variable.
Statistical analyses
Using standard statistical methods (Gehan, 1961), we used a 2-
stage design in this study. If no CR or PR was noted in the ﬁrst
14 patients, a response rate of 420% could be excluded with
95% conﬁdence and accrual was stopped. If at least 1 CR or PR
was observed, an additional 30 patients were entered in the study
for a target sample size of 44 patients. P-values were calculated
from the student t-test and values 50.05 were considered signiﬁ-
cant. For overall response rate, 95% conﬁdence intervals (CI)
were calculated as described by Anderson et al, 1982. Time to
response was measured from the ﬁrst dose of chemotherapy to
the onset of best response, duration of response was measured
from the onset of the best response to the date of disease progres-
sion, and overall survival from the ﬁrst dose of chemotherapy to
the date of death.
RESULTS
Tumour response and survival
Eleven patients responded to treatment, with 1 (2%) CR that lasted
for 26 months without additional therapy and 10 (23%) PR, for an
overall response rate of 25% (95% CI, 19–34%). The median time
to response was 2.3 months (range, 1.5–4.1 months), and the
median duration of response was 11.4 months (range, 13–26
months). An additional 18 (41%) patients reached SD, including
two who achieved minor responses lasting for a median of 6.1
months (range, 2.5–14.5 months). The remaining 13 patients
(30%) progressed. Out of the 44 enrolled patients, two discontin-
ued treatment after the ﬁrst and second cycle of the remaining 42,
38 were dead and four were alive as of the data cut-off date. The
median time to progression was 4.1 months (range, 1.9–19
months). The median survival duration was 10.9 months (range,
2–26 months), and the probability of surviving beyond 12 months
was 23%.
Clinical beneﬁt response
A total of 12 of the 27 (44.4%) patients with symptomatic pancrea-
tic cancer were classiﬁed as clinical beneﬁt responders; nine
patients (33.3%) experienced worsening of at least one variable.
Eight (29.6%) patients experienced an improvement in perfor-
mance status that was sustained for at least four weeks during
the study period. Nine (33.3%) patients suffering from pain at
study entry experienced a reduction of pain intensity and/or
analgesic use. With regard to weight gain, six (22.2%) patients
had a positive response (47% increase from baseline). The median
time to clinical beneﬁt response was 5 weeks (range, 3–10 weeks),
and the median duration was 28 weeks (range, 6–76 weeks).
Out of the 11 patients who achieved objective tumour responses,
only six were symptomatic, and of these, ﬁve were clinical beneﬁt
responders. We did not observe a correlation between clinical
beneﬁt response and tumour response (P=n.s). However, for the
patients who achieved a clinical beneﬁt response, median survival
was 9.6 months compared to 6.5 months for clinical beneﬁt
non-responders. While there were no differences in terms of
response rate, survival and clinical beneﬁt response between
patients with locally advanced vs metastatic disease.
Dose administration and toxicity
Patients received a total of 263 chemotherapy cycles. Thirty (71%)
patients received all of the planned seven cycles of GEM-EPI, while
the remaining patients received a median of four cycles (range, 2–
6 cycles). The mean total dose of drugs administered was
320 mg m
72 (range, 120–420 mg m
72) for EPI and
12000 mg m
72 (range, 6000–21000 mg m
72) for GEM. A total
of 85% of dose administrations were given on schedule, 6% were
delayed, 5% were reduced and 4% omitted.
The maximum WHO grades (grades 3) encountered during any
cycle of therapy are summarized in Table 2. With regard to bone
marrow toxicity, the treatment led to a suppression of leukocytes
and platelets (14 and 12% of cycles affected, respectively), as well
as a signiﬁcant decline in hemoglobin (anaemia in 4.8% of cycles)
and only one patient required RBC transfusion. Myelosuppression
tended to be cumulative, with lower and more prolonged nadirs
after four cycles. None of the patients required hospitalization
for sepsis referable to biliary tract infections or neutropenic fever,
and the six who experienced infections (mainly pulmonary) were
all manageable on an outpatient basis.
Only three patients had grade 3 gastrointestinal toxicity (diar-
rhoea). Mild nausea/vomiting (grade 1/2) occurred in 20 patients
(27% of cycles), and only a few patients had minor hair loss (grade
1/2 in 20 patients and 12% of cycles). Renal, hepatic and neurolo-
gic toxicities were generally mild, only one patient had grade 3
chemically-induced phlebitis. The mean total dose of EPI adminis-
tered was 320 mg
2 and no evidence of cardiac toxicity (WHO42)
was recorded.
DISCUSSION
Pancreatic adenocarcinoma is generally considered resistant to
cytotoxic therapy. As with other gastrointestinal malignancies, 5-
FU is the most widely investigated agent and produces tumour
response rates ranging from 0–20% and median survival times
of 4.2–5.5 months (Brennan et al, 1993). Modulation by folinic
acid, protracted venous infusion, or timing with circadian rhythms
seem to have only marginal effects on response rates and survival.
Recent phase II studies have reported promising clinical activity
with the combination of GEM and anthracycline derivatives in
advanced breast and non-small cell lung cancer (Lueftner et al,
1998; van Putten et al, 2000). In a phase II trial by Scheithauer
et al, 1999, 70 patients with metastatic pancreatic adenocarcinoma
received 4 weekly courses of GEM 1000 mg m
72 on days 1, 8, 15
plus EPI 60 mg m
72 on day 1. Out of the 66 patients evaluable for
response, there was an overall objective response rate of 21% (1
CR, 13 PR). Median survival was 7.8 months. We therefore decided
to combine GEM and EPI, as proposed by Scheithauer, but with a
different schedule. In our trial, patients received a weekly adminis-
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Table 1 Patient characteristics
Number of patients 44
Age, median/range (years) 59 (45–75)
Male/female (%) 30 (68.2)/14 (31.8%)
Karnofsky perfomance status No. (%)
50–60 6 (13.6)
70–80 29 (65.9)
90–100 9 (20.5)
Disease at presentation No. (%)
Locally advanced 24 (54.5)
Locally advanced and metastatic 20 (45.5)
Disease stage No. (%)
Stage III 10 (16.1)
Stage IV 34 (77.3)
Prior surgery, n (%)
None 18 (40.9)
Explorative laparotomy 18 (40.9)
Palliative by-pass 18 (40.9)
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attempt to exploit the synergistic action of the two drugs while
minimizing the overall toxicity. This regimen was associated with
promising activity in our patients with advanced pancreatic cancer.
Twenty-ﬁve per cent of patients attained an objective response, and
median survival for responding and nonresponding patients
combined was 10.9 months. Recently, there has been renewed
interest in single–agent chemotherapy with the advent of novel
agents such as irinotecan (response rate 11%) (Sakata et al,
1993) and docetaxel (response rate 20%) (Androulakis et al,
1999). Single-agent GEM has also been recently investigated for
activity as well as toxicity in advanced pancreatic cancer by Casper
et al, 1994 and Carmichael et al, 1996, who reported modest objec-
tive response rates of 6.3–11% and median survivals of 5.6–6.3
months; however, the symptomatic improvements were greater
than the objective tumour response rates would suggest. Conse-
quently, the National Cancer Institute and the Food and Drug
Administration (USA) have accepted that the relief of tumour-
related symptoms is itself a noteworthy goal of carcinoma treat-
ment (O’Shaughnessy et al, 1991). Given the palliative nature of
advanced disease, we reasoned that pancreatic carcinoma offered
an appropriate clinical setting in which to examine these alternative
endpoints. Thus, the current study evaluated clinical beneﬁt
response as an endpoint of efﬁcacy. We observed a palliative effect
in 44% of symptomatic patients; a similar rate (43%) was reported
by Scheithauer et al, 1999. Yet, consistent with Hidalgo et al, 1999;
half of patients who attained clinical beneﬁt did not achieve an
objective tumour response.
The results of this study also clearly demonstrated that the
GEM-EPI regimen was adequately tolerated, and was associated
with moderate toxic effects that were qualitatively and quantita-
tively similar to those reported in other malignancies (Lueftner et
al, 1998; van Putten et al, 2000). Leukopenia WHO grade 3 was
observed in 14% of patients; however, there were no episodes of
febrile neutropenia requiring hospitalization. Other common
nonhaematological toxicities such as nausea/vomiting and alopecia
were mild, and we did not observe any cardiac toxicity at this dose
of EPI.
In conclusion, this study demonstrates that weekly GEM plus
EPI is well tolerated and conﬁrms the observation of symptomatic
improvement in a reasonable proportion of patients with advanced
disease. In addition, the regimen is active with a good response rate,
and a long median survival duration. Our future efforts will focus
on randomized trials evaluating this GEM-EPI schedule in patients
with earlier-stage disease and/or as adjuvant chemotherapy.
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